S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
pixel
Log in
NASDAQ:AIMT

Aimmune Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$34.49
0.00 (0.00 %)
(As of 10/13/2020)
Add
Compare
Today's Range
$34.49
Now: $34.49
$34.49
50-Day Range
$34.30
MA: $34.46
$34.59
52-Week Range
$10.09
Now: $34.49
$37.00
VolumeN/A
Average Volume1.71 million shs
Market Capitalization$2.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Aimmune Therapeutics logo

MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

736th out of 1,923 stocks

Pharmaceutical Preparations Industry

371st out of 773 stocks

Analyst Opinion: 1.1Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220
Employees228

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.66 per share

Profitability

Net Income$-248,500,000.00

Miscellaneous

Market Cap$2.26 billion
Next Earnings DateN/A
OptionableOptionable

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

Is Aimmune Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Aimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AIMT, but not buy additional shares or sell existing shares.
View analyst ratings for Aimmune Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aimmune Therapeutics?

Wall Street analysts have given Aimmune Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aimmune Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Aimmune Therapeutics' CEO?

1,448 employees have rated Aimmune Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Aimmune Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) announced its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, meeting the consensus estimate of ($1.06).
View Aimmune Therapeutics' earnings history
.

What price target have analysts set for AIMT?

9 analysts have issued 1-year price targets for Aimmune Therapeutics' shares. Their forecasts range from $15.00 to $58.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $34.28 in the next twelve months. This suggests that the stock has a possible downside of 0.6%.
View analysts' price targets for Aimmune Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Aimmune Therapeutics' key competitors?

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the following people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $34.49.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $2.26 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is www.aimmune.com.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.